Clinical Trials Directory

Trials / Completed

CompletedNCT03716310

Platelet Reactivity in Septic Shock

Impaired Platelet Reactivity as an Early Biomarker for Sepsis-related Thrombocytopenia

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
Università degli Studi di Ferrara · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Coagulation disorders and thrombocytopenia are common in patients with septic shock. Despite the clinical relevance of sepsis-induced thrombocytopenia, few studies have focused on the prediction of thrombocytopenia in this setting. The aim of this study was to evaluate whether platelets aggregometry and markers of platelets activation, such as mean platelet volume or platelet volume distribution width, could predict sepsis-induced thrombocytopenia in patients with septic shock and normal platelet count on the day of diagnosis.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTplatelet responsiveness evaluationBlood samples were anticoagulated with 0.129 mmol/L of sodium citrate and then centrifugated for 10 min at 200 rpm; platelets aggregation was assessed with an AggRAM Advanced Modular System light transmittance aggregometer (Helena Laboratories, Beaumont, Texas, USA). Low-molecular-weight heparin (LMWH) was given at least 8 hours before any blood aggregation sample. Agonist used to initiate aggregation test were: -Adenosine diphosphate (ADP) to assess P2Y12-dependent platelet aggregation; (20 ng) - Arachidonic acid (AA) to assess cyclooxygenase-dependent platelet Adenosine diphosphate aggregation (1 mcg) - thrombin receptor-activating peptide-6 (TRAP-6) to assess protease-activated receptor 1-dependent platelet aggregation. Max aggregation reached (Aggmax), the slope of the curve (slope) and the latency time (lat) were analyzed for each agonist.

Timeline

Start date
2017-04-01
Primary completion
2018-05-30
Completion
2018-08-30
First posted
2018-10-23
Last updated
2018-10-23

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT03716310. Inclusion in this directory is not an endorsement.